Exercise in a pill? That's the focus of Cambrian's new pipeline company
In line with its anti-aging central theme, Cambrian BioPharma has a new clinical candidate to work with, going after what CEO James Peyer described as a “Holy Grail target.”
The New York drug developer announced the launch of its newest pipeline company, Amplifier Therapeutics, Tuesday morning. Cambrian is investing $26 million into Amplifier to kick things off, Peyer told Endpoints News. James Hall, the ex-head of cardiovascular BD at AstraZeneca, is at the helm as Amplifier’s CEO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.